PT-141, also known as Bremelanotide, is a synthetic peptide agonist of the melanocortin receptors (primarily MC3R and MC4R). Originally developed from Melanotan II, it was refined to minimize tanning side effects while enhancing sexual arousal effects. It’s FDA-approved as Vyleesi (injectable) for hypoactive sexual desire disorder (HSDD) in premenopausal women, but the 10mg vial form is typically used off-label for both men and women in research or performance contexts.

Key Facts

Primary Uses

• Sexual Dysfunction: Stimulates central nervous system pathways to increase libido, arousal, and genital blood flow. Effective for erectile dysfunction (ED) unresponsive to PDE5 inhibitors like Viagra, and female sexual arousal disorder.
• Mechanism: Bypasses vascular pathways (unlike Viagra); acts on brain melanocortin receptors to boost dopamine and arousal signals.
• Evidence:
  • Clinical trials (e.g., Phase III for Vyleesi): 25-50% improvement in sexual desire scores vs. placebo.
  • Studies in men (e.g., Rosen et al., 2004): 80% erectile response at 6mg doses.
  • User reports (anecdotal, forums like Reddit/Peptides): Strong libido boost, spontaneous erections, heightened sensitivity; works in psychogenic ED.

Reconstitution & Dosing for 10mg Vial

1. Reconstitution:

• Use bacteriostatic water (BAC). Refrigerate after mixing (stable 4-6 weeks).
• Gently swirl; do not shake.

2. Dosing Protocol:
   • Beginner: 0.5mg SC in abdomen/thigh.
   • Standard: 1-1.5mg (titrate up; max 2mg/dose).
   • Frequency: 1-2x/week; avoid daily use to prevent tolerance.
   • Cycle: 4-8 weeks on, 2-4 weeks off.

Side Effects

• Nausea peaks at higher doses; mitigate with antiemetics or lower dose.
• Contraindications: Heart disease, uncontrolled hypertension, pregnancy.

Sourcing & Legality

• Research Chemical: Sold as “not for human consumption” from peptide vendors (e.g., Peptide Sciences, Limitless Life). Purity >98% via HPLC/MS testing recommended.
• Prescription: Vyleesi auto-injector (1.75mg/dose) via pharmacy.
• Legal in most countries for research; gray area for personal use.

Evidence Summary

• Proven: FDA approval for women; multiple RCTs show efficacy (e.g., Diamond et al., J Sex Med 2011).
• Off-Label Strength: Superior to placebo in male ED trials (Wessells et al., 2000).
• Limitations: Not first-line; short-term data strong, long-term safety moderate.

Safety Note: Consult a physician before use. Self-administration carries risks like improper dosing or contamination. This is for informational purposes only.